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ABSTRACT
While the recent success of adeno-associated virus (AAV)-mediated gene therapy in clinical trials is promising, challenges still
face the widespread applicability of recombinant AAV(rAAV). Amajor goal is to enhance the transduction efficiency of vectors
in order to achieve therapeutic levels of gene expression at a vector dose that is below the immunological response threshold. In
an attempt to identify novel compounds that enhance rAAV transduction, we performed two high-throughput screens compris-
ing 2,396 compounds. We identified 13 compounds that were capable of enhancing transduction, of which 12 demonstrated vec-
tor-specific effects and 1 could also enhance vector-independent transgene expression. Many of these compounds had similar
properties and could be categorized into five groups: epipodophyllotoxins (group 1), inducers of DNA damage (group 2), effec-
tors of epigenetic modification (group 3), anthracyclines (group 4), and proteasome inhibitors (group 5). We optimized dosing
for the identified compounds in several immortalized human cell lines as well as normal diploid cells. We found that the group 1
epipodophyllotoxins (teniposide and etoposide) consistently produced the greatest transduction enhancement. We also ex-
plored transduction enhancement among single-stranded, self-complementary, and fragment vectors and found that the com-
pounds could impact fragmented rAAV2 transduction to an even greater extent than single-stranded vectors. In vivo analysis of
rAAV2 and all of the clinically relevant compounds revealed that, consistent with our in vitro results, teniposide exhibited the
greatest level of transduction enhancement. Finally, we explored the capability of teniposide to enhance transduction of frag-
ment vectors in vivo using an AAV8 capsid that is known to exhibit robust liver tropism. Consistent with our in vitro results,
teniposide coadministration greatly enhanced fragmented rAAV8 transduction at 48 h and 8 days. This study provides a founda-
tion based on the rAAV small-molecule screen methodology, which is ideally used for more-diverse libraries of compounds that
can be tested for potentiating rAAV transduction.
IMPORTANCE
This study seeks to enhance the capability of adeno-associated viral vectors for therapeutic gene delivery applicable to the treat-
ment of diverse diseases. To do this, a comprehensive panel of FDA-approved drugs were tested in human cells and in animal
models to determine if they increased adeno-associated virus gene delivery. The results demonstrate that particular groups of
drugs enhance adeno-associated virus gene delivery by unknownmechanisms. In particular, the enhancement of gene delivery
was approximately 50 to 100 times better with than without teniposide, a compound that is also used as chemotherapy for can-
cer. Collectively, these results highlight the potential for FDA-approved drug enhancement of adeno-associated virus gene ther-
apy, which could result in safe and effective treatments for diverse acquired or genetic diseases.
Adeno-associated viral (AAV) vectors have emerged to be oneof the most promising types of vectors for gene therapy. In-
deed, recent and ongoing clinical trials have reported improve-
ments in patients with hemophilia B (1), Parkinson’s disease (2,
3), Leber congenital amaurosis (4–7), and Canavan disease (8).
Such clinical successes have led to the approval of recombinant
AAV (rAAV)-mediated gene therapy in the European Union for
the treatment of lipoprotein lipase deficiency (LPLD) (9). Enthu-
siasm for using rAAV vectors stems from the unique properties of
the virus itself. As naturally occurring AAV requires a helper virus
such as adenovirus or herpes simplex virus in order to carry out a
productive infection, AAV on its own is not known to cause dis-
ease in humans. AAV vectors are comprised of transgenic DNA
(5 kb) with the only viral sequence being the 145-nucleotide
inverted terminal repeats (ITRs). Furthermore, naturally occur-
ring serotypes and engineered capsids have been shown to display
diverse tissue tropism, as well as the ability to infect both dividing
and nondividing cells (for a review, see reference 10). From a
vector perspective, the use of AAV for gene therapy applications is
limited only by the size of the vector, which consists of a transgene
of approximately 4.7 kb (11). However, even the size limitations of
rAAV vectors are being challenged with the development of trans-
splicing and fragment vector (fAAV) technology; that is, transgene
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cassettes that rely on cellular recombination pathways to restore a
full-length, large genome upon delivery by multiple rAAV vectors
(12–19).
Despite its remarkable safety profile, gene therapy using AAV
vectors has had limited success in applications requiring systemic
delivery, namely, to nonimmunoprivileged sites (as opposed to
direct injection into various tissues or to immunoprivileged re-
gions). Results from clinical trials utilizing either rAAV2 or
rAAV8 to deliver human factor IX to hemophilia B patients have
suggested that capsid-specific cytotoxic T lymphocytes (CTLs)
might have eliminated the majority of transduced cells, thus im-
peding successful gene expression (1, 20). In these dose escalation
trials, therapeutic protein levels were achieved at the highest vec-
tor doses administered; however, these levels were transient and
their decline corresponded with a rise in liver transaminases, sug-
gestive of transduced cell death. There was no rise in liver enzymes
detected at the lower doses tested, suggesting that gene transfer to
achieve protein levels that would be deemed therapeutic is limited
by the amount of capsid that can be delivered to the host (21). It
has thus been postulated that if transduction efficiency could be
improved (including both gene transfer and expression), fewer
vectors would be required to achieve a given level of gene expres-
sion, and thus a clinically relevant therapeutic protein level could
be obtained without eliciting a host immune response (22).
Several strategies have been employed in order to enhance
transduction efficiency. Both rational mutagenesis and library-
based approaches have been designed to create capsids that have
increased transduction efficiency for particular tissue types as well
as decreased tropism for nontarget organs such as the liver (23–
28). Barriers within the intracellular trafficking pathway have also
been circumvented based on rationally engineered capsids (29,
30). Improvements to transgene design, including self-comple-
mentary rAAV and tissue-specific promoters, ensure faster and
more-robust onset of gene expression in target tissues (31–34).
Finally, enhancing transduction efficiency through the use of
pharmacological agents has been explored. Previous work has
shown that topoisomerase inhibitors and anthracyclines can en-
hance transduction both in vitro and in vivo (35–42). Proteasome
inhibitors, particularly the FDA-approved bortezomib (Velcade),
have been shown to enhance transduction in vitro as well as in
both small- and large-animal models (39, 40, 43). Collectively,
these strategies have been important in reaching the level of trans-
duction required for therapeutic benefit without eliciting a host
immune response; however, efficient transduction in a wide vari-
ety of clinical applications is still a major goal that is actively being
pursued.
In this study, we performed a high-throughput, small-mole-
cule screen with the purpose of identifying additional compounds
that enhance rAAV2 transduction. Validation of this approach
was confirmed by the transduction augmentation of the previ-
ously identified topoisomerase II inhibitors, anthracyclines, and
proteasome inhibitors in our small-molecule screen. Addition-
ally, we identified several novel compounds and further char-
acterized those with reported functions based on existing liter-
ature. Collectively, these transduction-enhancing compounds
could be grouped into 5 categories: epipodophyllotoxin topo-
isomerase II inhibitors (group 1), DNA damage inducers (group
2), effectors of epigenetic modification (group 3), anthracyclines
(group 4), and proteasome inhibitors (group 5). We also identi-
fied a single agent that enhanced rAAV2 transduction through an
unrelated mechanism. The ability of these compounds to enhance
transduction was confirmed in vitro using several human cell
lines, including a normal diploid cell line, NHF-1. Some of these
compounds were shown to be effective in enhancing self-comple-
mentary rAAV2 (scAAV2) but to a lesser extent than single-
stranded rAAV2. Interestingly, the compounds exerted the great-
est degree of enhancement on fAAV2, restoring transduction to
levels equivalent to or surpassing that of single-stranded rAAV2.
We further examined the activity of compounds identified in our
screen that are currently approved for clinical use in vivo and
found that, consistent with our in vitro results, one such com-
pound—teniposide— exhibited the greatest level of transduction
enhancement. Given the impact of teniposide on fAAV2, we ex-
plored its capability to enhance transduction of fragment vectors
in vivo using an AAV8 capsid that is known to exhibit robust liver
tropism. Consistent with our in vitro results using fAAV2, tenipo-
side coadministration enhanced fragmented rAAV8 transduction
both at 48 h and through the duration of the experiment (8 days).
Our results demonstrate a simple, effective method of discovering
compounds that enhance rAAV2 transduction. We anticipate that
this approach can be applied to vectors derived from other sero-
types and in other cell lines. Furthermore, our design provides a
foundation to investigate the plethora of commercially available
compound libraries that span the small-molecule and FDA-ap-
proved drug milieu.
MATERIALS AND METHODS
Cell culture. HeLa cells, U87 cells, and normal human fibroblasts
(NHF1s) were grown in Dulbecco’s modified Eagle medium that was
supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml pen-
icillin, and 100 g/ml streptomycin (complete DMEM). HepG2 cells were
grown in RPMI 1640 medium, supplemented as described above. All cell
lines were maintained at 37°C and 5% CO2.
Virus production. Virus was produced in HEK-293 cells as previously
described (44). Briefly, using polyethylenimine (PEI) Max (Polysciences),
cells were triple transfected with a Rep and Cap plasmid (pXR2 or pXR8),
an inverted terminal repeat-flanked transgene plasmid (single-stranded
pTR-CBA-Luciferase, self-complementary pTR-CMV-gaussia-Lucifer-
ase, or oversized pTR-CBA-Luciferase, where CBA is chicken-beta actin
and CMV is cytomegalovirus), and the pXX6-80 helper plasmid. Between
48 and 72 h posttransfection, cells were harvested and virus was purified
by cesium chloride gradient density centrifugation overnight at 55,000
rpm. Fractions that contained peak virus titers were dialyzed in dialysis
buffer (1 phosphate-buffered saline [PBS], 0.5% sorbitol, 0.5 mM cal-
cium chloride, and 1 mM magnesium chloride). Titers were calculated by
quantitative PCR (qPCR) according to established procedures (16) by
using a LightCycler 480 instrument with Sybr green PCR master mix.
Conditions used for the reaction were as follows: 1 cycle at 95°C for 10
min; 45 cycles at 95°C for 10 s, 62°C for 10 s, and 72°C for 10 s; and 1 cycle
at 95°C for 30 s, 65°C for 1 min, and 99°C for acquisition.
Compound screen, 384-well format.HeLa cells were plated at least 18
h prior to compound treatment and infection at a density of 8  103
cells/well. Compounds were prepared in complete DMEM so that delivery
would yield a final concentration of 1 M. Compounds were added di-
rectly to wells. Two hours posttreatment, rAAV2-CBA-Luciferase was ad-
ministered at a dose of 1,000 vector genomes (vg)/cell. Cells were har-
vested 24 h postransduction by medium removal followed by incubation
with passive lysis buffer (Promega) for 15 min. Luciferase activity was
measured in accordance with the manufacturer’s instructions (Promega).
Luciferase activity was measured either a PerkinElmer 1450 MicroBeta
TriLux LSC and luminescence counter or a PerkinElmer 2450 MicroBeta2
microplate counter. Compounds that enhanced transduction 2-fold
over dimethyl sulfoxide (DMSO) treatment were considered hits for fur-
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ther study. Cell viability was measured using the CellTiterGlo luminescent
cell viability assay (Promega).
Secondary screen, 96-well format. HeLa cells were plated at least 18 h
prior to compound treatment and infection at a density of 2 104 cells/
well. Compounds were prepared in complete DMEM at a concentration
of 10 M. Medium was replaced with medium containing each com-
pound. Two hours posttreatment, rAAV2-CBA-Luciferase was adminis-
tered at a dose of 500 vg/cell. Cells were harvested 24 h postinfection via
incubation with passive lysis buffer (Promega) for 15 min. Luciferase
activity was measured in accordance with the manufacturer’s instructions
(Promega). Luciferase activity was measured with a Wallac 1420 Victor3
plate reader. Compounds that enhanced transduction 5-fold over
DMSO treatment were considered hits for further study.
Transduction assays. Cells were plated at least 18 h prior to infection
in 96-well plates at a density of 2 104 cells/well. Compound treatment
was performed 2 h prior to infection. Compounds were either provided by
the Drug Testing Program or were commercially available (teniposide
from Sigma; nanaomycin from Apex Bio; daunorubicin and vorinostat
from LC Laboratories). Cells were infected with purified rAAV2-
CBA_Luc at 500 vector genomes/cell. Cells were harvested 24 h postinfec-
tion, and luciferase activity was determined as described above. For
scAAV, cells were treated as described above. At 24 h postinfection, 20 l
of medium was transferred to a black 96-well plate. The luciferase assay
was performed using coelenterazine (Nanolight) as the reagent. Briefly,
the coelenterazine was resuspended to 10 mg/ml in methanol. To make
the working solution, the concentrated stock was dissolved in Tris-EDTA
(TE) buffer containing NaCl (0.6 M) at a 1:200 dilution. The working
solution was added to the wells at a 1:1 ratio of medium to coelenterazine,
and luciferase activity was recorded.
Transfection assays. Two million HeLa cells were plated at least 18 h
prior to transfection in a 10-cm plate. Cells were transfected with 1 g
pTR-CBA-Luc using PEI Max. Twenty-four hours posttransfection, cells
were plated in a 96-well plate at a density of 2  104 cells/well. At 48 h
posttransfection, cells were treated with the indicated drugs. At 72 h post-
transfection, cells were harvested and luciferase activity was measured.
Animal studies. Housing and handling of BALB/c mice used in the
study were carried out in compliance with National Institutes of Health
guidelines and approved by the IACUC at the University of North Caro-
lina Chapel Hill. All drugs and rAAV-Luc were coadministered through
the intravenous route (tail vein) in a total volume of 200 l (normalized
with l PBS). For toxicity analysis, 24 h postadministration blood was
collected and serum was assessed for blood urea nitrogen (BUN), aspar-
tate aminotransferase (AST), alanine aminotransferase (ALT), and crea-
tine kinase (CK). Bioluminescence of Luc expression was visualized by
using a Xenogen IVIS Lumina imaging system (PerkinElmer) following
intraperitoneal injection of luciferin substrate (120l; Nanolight). Image
acquisition and analysis were carried out by using Living Image software.
RESULTS
Primary and secondary screens.The overall goal of our study was
to identify and characterize small molecules that enhanced rAAV
transduction in vitro and, if the small molecule was FDA approved
at the time, in vivo. Two screens were performed to identify such
compounds. The first was a stringent screen using a 1 M final
compound concentration to identify compounds capable of po-
tentiating rAAV2 transduction at low concentrations. In each
plate, column 1, row 1 contained no virus and no compounds,
column 2, row 2 contained rAAV2 but no compounds. Column
24, row 4 contained 1 M MG132 as a positive control. Column
23, row 3 contained rAAV2 with only DMSO (vehicle control). All
compounds were administered in duplicate. Finally, each plate
contained two sets of the given controls and compounds, whereby
rows 1 to 8 (top, gray) were assayed for transduction activity and
rows 9 to 16 (bottom, white) were assayed for viability using the
CellTiterGlo system. As the vast majority of AAV biology has been
discovered using AAV2 or rAAV2 in HeLa cells, our primary and
secondary screens were performed using these parameters. Owing
to its wide range in output and linear relationship to vector dose,
the CBA-luciferase transgene, and thus luciferase activity, was
chosen as the reporter for transduction efficiency. A secondary
screen utilized a high (10 M) final compound concentration in
tandem with employing rAAV2 to HeLa cells at 500 vg/cell. The
format of this screen utilized DMSO added to all wells in column
1, row 1 as a vehicle control, while two wells in column 12, row 2
contained MG132 as a positive control. Cell viability was not as-
sessed at this stage. A combined list of the compounds that were
pursued further is provided in Table 1.
TABLE 1 Compounds characterized in this studya
Group no. Compound name NSC IDb Clinical use Group Known mechanism of action
1 Teniposide 122819 Chemotherapy Podophyllotoxin Topoisomerase II inhibition
Etoposide 141540 Chemotherapy
2 Bleomycin 125066 Chemotherapy, plantar warts Glycopeptide antibiotic DNA damage
Parthenin 85239 Sesquiterpene lactone
RH-1 697726 Phase I, solid malignancies Diaziridinylbenzoqui none
3 Vorinostat 701852 Chemotherapy HDAC inhibitor HDAC inhibition
Nanaomycin A 267461 DNMT3B inhibitor DNMT3B inhibition
4 Menogaril 269148 Anthracycline DNA intercalation, topoisomerase
II inhibition, polymerase
inhibition, free radical damage
to DNA
Pyrromycin 267229
Daunorubicin 82151 Chemotherapy
5 Bortezomib 681239 Chemotherapy Dipeptide Proteasome inhibition
Physalin B 287088 Physalin
Siomycin 285116 Thiazole antibiotic
Tetrocarcin A 333856 Microbial metabolite BCL-2 inhibitor
a Compounds that emerged as hits were selected based on known function in cells or clinical utility.
b NSC ID, National Service Center identifying number.
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In the primary screen, an initial “hit” was defined as a com-
pound that enhanced transduction at least 2-fold, while in the
secondary screen, an initial “hit” was defined as a compound that
enhanced transduction at least 4-fold. From the hits found in both
screens (a total of 72), we chose to further study compounds that
had known functions based on existing literature. However, it is
noteworthy to mention that several compounds with as-yet-un-
known function were identified as hits, some enhancing transduc-
tion 5- to 10-fold. These compounds warrant validation in further
studies, but further characterization was deferred in order to bet-
ter understand the compounds with reported mechanisms of ac-
tion. Of these hits, compounds could be further categorized into
groups based on their known cellular mechanisms of action (Ta-
ble 1). Group 1 compounds included the epipodophyllotoxins
teniposide and etoposide, which have been shown to inhibit topo-
isomerase II activity and cause DNA damage. Of these, etoposide
has been previously identified as having rAAV2 transduction-po-
tentiating activity, likely through mechanisms related to DNA
damage repair proteins induced by etoposide-mediated inhibition
of topoisomerase II (38). Group 2 compounds comprised other
small molecules that are known to cause DNA damage, although not
necessarily through topoisomerase II inhibition. These included the
glycopeptide antibiotic bleomycin, which is known to cause DNA
double-strand breaks (45), the sesquiterpene lactone parthenin,
which has been shown to induce chromatid breaks (46), and the
diaziridinylbenzoquinone RH1, a DNA cross-linker (47).
Group 3 compounds, nanaomycin A and vorinostat, are char-
acterized by their ability to facilitate epigenetic modifications of
DNA. While the quinine antibiotic nanaomycin A has been shown
to generate oxygen free radicals and cause DNA damage (48, 49),
it has also recently been identified as an inhibitor of DNA meth-
yltransferase 3B (DNMT3B) (50), thereby inhibiting epigenetic
repression of gene expression. Vorinostat (suberanilohydroxamic
acid [SAHA]) belongs to the class of histone deacetylase inhibi-
tors, which function in cells to cause an accumulation of acety-
lated histones and transcription factors, which in general increases
gene expression (51, 52). Group 4 compounds consisted of an-
thracyclines, which are compounds that have been shown to exert
a variety of effects, including inhibition of topoisomerase and
proteasomal activity. These compounds included menogaril, pyr-
romycin, and the chemotherapeutic daunorubicin. A related an-
thracycline, doxorubicin, has been characterized for its enhance-
ment of rAAV transduction (39, 40); therefore, it is likely that
these other anthracyclines potentiate rAAV transduction through
similar mechanisms.
We also identified several nonanthracycline compounds that
have been shown to have proteasome-inhibiting activity (group
5). These included bortezomib, physalin B, and siomycin. Bort-
ezomib, an FDA-approved proteasome-inhibiting agent, has been
explored for rAAV applications in a variety of cell lines and animal
models and using different serotypes (43, 53–56). Thus, the iden-
tification of bortezomib within the screen inadvertently served as
an internal control in validating our experimental setup. In addi-
tion to its proteasome-inhibiting properties (57), physalin B has
also been shown to have anti-inflammatory and other immuno-
modulatory activity (58). The proteasome-inhibiting activity of
siomycin has been correlated with its role as an inhibitor of the
transcription factor forkhead box M1 (FOXM1) (59–61).
Finally, we identified one compound, tetrocarcin A, that could
not be categorized into any of groups 1 to 4 but did show modest
levels of rAAV2 transduction enhancement. Tetrocarcin A has been
shown to inhibit the antiapoptotic function of Bcl-2 (62) and induce
endoplasmic reticulum (ER) stress (63), the latter condition of which
we previously demonstrated to increase transduction (64).
In addition, our screen yielded several compounds that are
known to interfere with microtubule dynamics, including colchi-
cine, vincristine, and vinblastine, among others; however, these
were excluded from further study as it has already been demon-
strated that these microtubule inhibitors inhibit the cell cycle at
low concentrations (65), which is likely the mechanism behind
their transduction enhancement. In fact, at higher concentrations,
these drugs have been shown to inhibit viral trafficking to the
nucleus as well as transduction (66, 67).
Dose optimization of compounds in HeLa cells. In order to
further characterize the active compounds from our screen, we
wanted to determine an optimal concentration that would result
in the greatest enhancement of transduction without causing
overt toxicity. To avoid potential side effects caused by DMSO, the
final concentration of compounds was limited to 100 M for
high-dose applications. Based on these concentration boundaries,
it is possible that compounds that both were well tolerated by cells
and substantially enhanced transduction at higher concentrations
(such as etoposide and bleomycin) may be capable of enhancing
transduction at an even greater level than what was determined
under our experimental conditions. For some compounds, the
therapeutic window was quite small in that there was a very sharp
decrease in cell viability as the concentration of the compound was
increased. A notable example was menogaril, which at 5 M
showed a10-fold enhancement and approximately 100% viabil-
ity but at 10 M resulted in an approximately 50% reduction in
viability, which corresponded to a reduction in transduction en-
hancement as well (data not shown). The epipodophyllins tenipo-
side and etoposide, as well as the DNA-damaging agent bleomy-
cin, were the strongest augmenters in this assay, each increasing
transduction over 20-fold. The proteasome inhibitors bortezomib
and physalin B also showed enhancement over 10-fold.
Effects of compounds on vector transduction versus general
gene expression. Given the identified compounds’ impressive
utility across multiple cell lines, it was important to investigate
whether the observed increase in transgene expression was due to
a mechanism related specifically to rAAV vectors. To this end,
HeLa cells were transfected with pTR-CBA-Luc, the transgene
plasmid used to generate the above-described single-stranded vec-
tor constructs, and assayed for enhancement of luciferase activity
following compound administration (Fig. 1). Most compounds
elicited a negligible change in luciferase activity. For example,
physalin B induced an approximately 2-fold increase in plasmid
luciferase expression but a 10-fold increase in transduction,
Some of the compounds even elicited a decrease in gene expres-
sion when tested with the plasmid vector cassette. The only excep-
tion was the histone deacetylase (HDAC) inhibitor vorinostat,
which increased luciferase expression of the transfected plasmid to
an extent similar to that seen with incoming vectors. It is noted
that increased plasmid-borne transgene expression in this case
does not simply imply that a similar mechanism of enhancement
occurs with AAV vectors. However, in attempts to focus on drug
enhancement of AAV vectors specifically, vorinostat was excluded
from further analysis.
Characterization of compound activity in human cell lines.
Given the ability of the identified compounds to enhance the
Nicolson et al.
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transduction of rAAV2 in HeLa cells (Fig. 2A), we further ex-
plored the utility of these compounds in different cell types to
better understand their potential universal utility. The first such
cell line examined was U87, a human glioblastoma cell line that is
amenable to rAAV2 transduction (Fig. 2B). Overall, the fold en-
hancement of each of the compounds was very similar to what was
observed in HeLa cells, with a few exceptions. While teniposide
enhanced transduction approximately 40-fold in HeLa cells, en-
hancement was seen at 20-fold in U87 cells. Interestingly, while
bortezomib enhanced transduction by approximately 15-fold in
HeLa cells, enhancement was only approximately 3-fold in U87
cells. However, the level of enhancement obtained with by another
compound with proteasome-inhibiting activity, physalin B, re-
mained similar in both cell lines (12-fold in HeLa cells and 10.5-
fold in U87 cells). We next evaluated these compounds in HepG2
cells, a hepatocellular carcinoma cell line, as the liver is the site of
transduction for systemically delivered rAAV2 (Fig. 2C). For
treatment with pyrromycin, nanaomycin A, physalin B, bort-
ezomib, and tetrocarcin A, transduction enhancement was ob-
served at approximately the same magnitude as that seen with
HeLa cells. Treatment with the epipodophyllotoxins, anthracy-
clines, siomycin, and RH-1 resulted in enhancements 4- to
12-fold greater than that observed in HeLa cells. Notably,
menogaril, which enhanced rAAV2 transduction in HeLa cells
approximately 12-fold, enhanced transduction in HepG2 cells
138-fold. Finally, our compound collection was applied to
NHF1 cells (a kind gift from William Kaufman), a diploid cell
line derived from neonatal foreskin and immortalized by the
expression of telomerase reverse transcriptase (hTERT) that
displays contact inhibition and stationary growth once conflu-
ent (68) (Fig. 2D). Again, treatment with the epipodophyllo-
toxins and anthracyclines (especially menogaril) significantly
enhanced transduction at magnitudes much greater than what
was observed in HeLa cells. Treatment of NHF-1 cells with
bleomycin also resulted in impressive transduction enhance-
ment (approximately 100-fold). These results suggest that in
general, the group 1 epipodophyllotoxins, causing DNA dam-
age from topoisomerase II inhibition, consistently yielded the
greatest enhancement in transduction. Proteasome inhibition,
particularly by bortezomib, was more variable and cell type
dependent. It is possible that the enhancing ability of these
FIG 1 Effects of compounds on plasmid gene expression. HeLa cells were
transfected with pCBA-Luc and treated with the compounds identified in our
screen. Transduction was assessed 24 h after compound treatment. Of the hits,
vorinostat appears to be the only compound that enhances plasmid gene ex-
pression.
FIG 2 Effects of compounds on human cell lines. Cells were treated with the identified compounds or dose-appropriate DMSO and later rAAV2_CBA-Luc.
Transduction was assessed 24 h after drug treatment. (A) HeLa cells; (B) U87 cells; (C) HepG2 cells; (D) NHF1 cells.
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compounds depends on the abundance of their actionable tar-
gets within cells. Thus, these results highlight the differences in
response to pharmacological modulation in different cell types,
which may influence the type of agent chosen to complement
rAAV-mediated gene therapy in a given target tissue.
Characterization of transduction-specific compound activ-
ity with vectors comprised of differentially formed transgenes.
Recent and emerging gene therapy applications have utilized
transgenes that differ in form from the prototypical single-
stranded AAV genome. For example, self-complementary vectors
contain a transgene whereby a third inverted terminal repeat
(ITR) in the middle of the transgene is mutated to eliminate the
Rep nicking stem (33). This yields a double-stranded gene prod-
uct, thus eliminating the rate-limiting step of second-strand syn-
thesis and providing a faster, more robust onset of expression (33,
69). Other emerging vectors designed to deliver large transgenes
are derived from the forced packaging of oversized genomes into
the viral capsid (13, 15, 16, 18, 19, 70). It is thought that the
packaged DNA becomes truncated at the 5= end once AAV has
reached its packaging limit, but delivery of these transgene “frag-
ments” still results in expression of the intact transgene through a
reannealing process modulated by the homologous recombina-
tion protein Rad51C (16). However, the transduction efficiency of
fAAV is impaired compared to that of rAAV or scAAV.
We therefore wanted to test the capabilities of the screen-iden-
tified compounds in enhancing the transduction of scAAV and
fAAV in HeLa cells. For scAAV, a vector carrying a cytomegalovi-
rus promoter-driven Gaussia luciferase transgene (CMV-gLuc)
was utilized. For fAAV, a previously described vector carrying the
same promoter and transgene as the single-stranded vector (CBA-
Luc), but with an additional 2.3-kb “stuffer sequence” inserted
into an intronic region upstream of the luciferase (16), was uti-
lized. A schematic of each of these vector transgenes is provided in
Fig. 3A. We applied the same optimized concentration of each
compound and tested their ability to enhance scAAV and fAAV
transduction at the same vector dose. With the exception of
daunorubicin and tetrocarcin A, the compounds still enhanced
scAAV transduction, but the magnitude of the effect was signifi-
cantly reduced (Fig. 3B). This suggests that these compounds may
also be acting at the step of second-strand (ss) synthesis. Since we
still observed enhancement of scAAV, albeit at a reduced capacity
compared to ssAAV, it is likely that these compounds augment
steps in transduction either before second-strand synthesis (such
as subcellular trafficking, nuclear entry, or uncoating) or in estab-
lishing the persistence of gene expression following second-strand
synthesis. Impressively, application of the compounds in con-
junction with fAAV2 enhanced transduction to a much greater
extent than with rAAV2 (Fig. 3C). Notably, treatment with teni-
poside, bortezomib, or bleomycin enhanced transduction over
250-fold, which was an 8- to 10-fold increase over the enhance-
ment seen in rAAV2. This result is particularly interesting, as each
of these drugs produces a different reported effect within cells. In
untreated cells, fAAV2 transduction was approximately 21- to 28-
fold lower than intact rAAV2, which is in agreement with previ-
ously reported results comparing fAAV2 and intact rAAV2 at
5,000 vg/cell (16). Treatment with any of the compounds restored
transduction of fAAV2 to levels (i) above untreated intact rAAV2
levels and (ii) within 2- to 10-fold of drug-treated intact rAAV2
FIG 3 Effects of identified compounds on vectors with different forms of transgenes. (A) Schematic of each of the transgene cassettes utilized in this study. Top,
single-stranded, intact; middle, self-complementary; bottom, fragment. HeLa cells were treated with each of the identified compounds and single-stranded
rAAV2 (B), scAAV2 (C), or fAAV2 (D) or dose-appropriate DMSO. Luciferase activity was measured 24 h following compound treatment.
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levels, depending on which compound is used. Taken together,
these results suggest that the identified compounds can enhance
the transduction efficiency of vectors with different forms of
transgenes and disproportionately benefit fAAV2 transduction in
HeLa cells.
In vivo analysis of FDA-approved hits. Owing to the appeal of
repurposing FDA-approved drugs to augment rAAV-mediated
gene transfer, we performed an in vivo comparison of rAAV2
transduction-potentiating capabilities of the hits identified in our
screen that are already FDA approved. Therefore, teniposide, eto-
poside, bleomycin, daunorubicin, and bortezomib were assessed.
The doses selected for in vivo study were chosen based on conver-
sions from the FDA-approved dosing in humans to the murine
equivalent based on body surface area and established Km factors
(71). As teniposide and etoposide are recommended for use over a
wide range of doses, they were administered in this study at a
conservative dose of 20 mg/kg of body weight (human equivalent
dose, (60 mg/m2). Each pharmaceutical was coadministered with
1  1011 vg rAAV2-CBA-Luc through tail vein injection in age-
matched female BALB/c mice. Two vehicle cohorts were included
in the study. We evaluated toxicity by measuring the levels of
blood urea nitrogen (BUN), aspartate transaminase (AST), ala-
nine transaminase (ALT), and creatine kinase (CK). These levels
appeared within normal ranges and were comparable to those in
the vehicle-treated mice. Average levels were similar for drug-
treated and vehicle-treated cohorts (data not shown).
Due to the impressive enhancement that we observed in vitro at
24 h postransduction, an early time point of gene expression was
measured to determine whether the pharmaceuticals could also
provide rapid, high-level gene expression in vivo. At 48 h postad-
ministration, all of the selected drugs enhanced transduction in
vivo, but to various degrees (Fig. 4A). Consistent with what was
seen in vitro, the epipodophyllotoxins as well as daunorubicin
enhanced transduction to the greatest extent. Notably, cotreat-
ment with teniposide enhanced transduction an average of nearly
100-fold (Fig. 4B). While teniposide and etoposide have the same
mechanism of action in cells (i.e., inhibition of the religation of
DNA ends through interference of the DNA-topoisomerase com-
plex), teniposide was a more potent augmenter of transduction at
this time point at the given dose. Upon assessment of transduction
8 days postadministration, enhanced transduction was noted
among all of the drug-treated cohorts (Fig. 4A). Teniposide coad-
ministration yielded the greatest enhancement in transduction at
this time point, followed by bortezomib. Daunorubicin cotreat-
ment also yielded impressive transduction enhancement at the 8
day time point. Bleomycin and etoposide cotreatment produced
only modest enhancement of transduction efficiency. This result
could be reflective of the in vivo dose limitations in order to reflect
clinical levels of each drug. In general, variability among treatment
groups, including vehicle-treated mice, was noticed and could
have been due to either an immune response against the luciferase
transgene in some mice, as has been historically observed, or per-
haps an effect of the vehicle (DMSO) on in vivo transduction.
Because coadministration of rAAV2 with teniposide showed the
most-robust transduction enhancement, and because of the robust
enhancement observed for fAAV2, we chose to test the ability of teni-
poside to enhance fragment rAAV in vivo as well. Due to the limited
systemic transduction capability of fAAV in vivo (16), we chose to test
the transduction using an AAV8 capsid, as intact rAAV8 vectors have
been shown to exhibit strong liver transduction (1, 44, 72). Due to the
difficulty in producing high-titer fAAV8, mice were administered
only 5  1010 vg. At 48 h postransduction, the teniposide-treated
cohort exhibited 34-fold-higher levels of luciferase activity than the
vehicle-treated cohort. Impressively, this enhancement was even
greater at 8 days postransduction, with the teniposide-treated cohort
exhibiting 86-fold-higher luciferase activity than the vehicle-treated
cohort (Fig. 5B).
Taken together, these results confirmed our observations in
vitro and corroborated that the greatest transduction augmenta-
tion arises from cotreatment with topoisomerase or proteasome
inhibitors. Furthermore, teniposide was shown to exhibit a robust
effect on fAAV8 transduction.
DISCUSSION
Recent gene therapy applications using rAAV have been met with
both success and challenges that depend on the indication, route
of administration, serotype, and vector dose utilized. Indeed, clin-
ical efficacy for one indication, lipoprotein lipase deficiency, has
been achieved to the extent that the first-ever gene therapy prod-
uct, an rAAV1 vector carrying a lipoprotein lipase transgene, is
now approved for use in the European Union (9). Results from
clinical trials have exposed the current limitations of rAAV-medi-
ated gene therapy, one of which is the lack of ability to achieve
robust, long-term therapeutic gene expression without eliciting
an immune response induced by high vector doses. Several strat-
egies have been employed to combat this challenge, including cap-
sid and transgene modification as well as pharmaceutical inter-
vention; however, they have been met with varied success and may
be limited to a particular serotype or tissue target. For example,
the elimination of certain tyrosines on the capsids of AAV2 and
AAV6 has allowed for enhanced transduction efficiency and lower
rates of proteasomal degradation (29, 30, 73); however, it has been
shown that this strategy cannot be applied to rAAV9 and attempts
with rAAV8 have produced mixed results (74, 75). Similarly, the
proteasome inhibitor bortezomib has been shown to enhance
transduction of both rAAV2 and rAAV8 vectors, resulting in in-
creased transgene expression in both small- and large-animal
models (43, 54, 55); however, a recent report has shown that this
strategy cannot be applied for rAAV9-mediated therapy for car-
diac failure (76). Thus, the need for a robust, widely applicable
strategy to enhance transduction would be highly beneficial in the
translation of rAAV-mediated gene therapy to a broad range of
applications. In addition, compounds that enhance rAAV trans-
duction may fall into classes that are tissue preferred; therefore,
new compounds will always be of interest to explore.
In this study, we employed a high-throughput small-molecule
screen to identify compounds capable of enhancing rAAV2 trans-
duction. Several compounds were identified, including some of
novel origin and some that have been previously defined. These
compounds were shown to have various activities on vectors com-
prised of different forms of transgenes, as well as some differential
effects in a variety of cell lines. Finally, selected compounds that
are currently being used in clinical applications were validated in
vivo. Overall, the greatest enhancers of transduction were drugs
that inhibit topoisomerase II, in particular, the group 1 epipodo-
phyllotoxins and the group 4 anthracyclines. Generalizing from
the entire collection of our identified hits, it seems that rAAV can
be enhanced by two mechanisms: (i) inhibition of the proteasome
and (ii) induction of DNA damage, which corroborates previously
published results (38, 39, 69, 77, 78).
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The epipodophyllotoxin and anthracycline topoisomerase II
inhibitors form complexes with DNA and topoisomerase II, an
enzyme required for the prevention of DNA supercoiling in eu-
karyotes. The topoisomerase II cycle includes (i) binding and
cleavage of duplexed DNA, (ii) passage of a second strand of DNA
through the complex, and (iii) religation of the broken DNA ends
(79). Both classes of topoisomerase II inhibitors prevent the reli-
gation step of this cycle, thus causing both single-stranded and
double-stranded DNA damage. While the direct role of topoisom-
erase II in the mechanism of rAAV transduction enhancement
cannot be ruled out, previous research suggests that the DNA
damage response, an indirect result of topoisomerase II inhibi-
tion, is likely the main contributor to the increase in transduction,
either through increased second-strand synthesis or by a currently
unknown mechanism (38, 80, 81). Indeed, this screen identified
several topoisomerase II-independent DNA-damaging agents,
such as bleomycin, parthenin, and RH1, as potentiators of rAAV2
transduction. In fact, bleomycin enhanced transduction to levels
similar to those of teniposide and etoposide treatment in U87 cells
(Fig. 1A). Several groups have shown that proteins involved in the
DNA damage response, including both homologous recombina-
tion and nonhomologous end joining, interact with incoming vi-
FIG 4 Analysis of transduction enhancement by compounds in vivo. (A) Live bioluminescent imaging of mice that were cotreated with rAAV2_CBA-Luc and
each of the clinically relevant compounds, imaged 48 h and 8 days postransduction. (B) Quantification of bioluminescent imaging. (C) Fold difference in
luciferase expression over vehicles.
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ral and vector genomes and have important roles in genome pro-
cessing. These processes are thought to include the conversion of
the single-stranded genome into double-stranded DNA (69, 82),
opening of ITR hairpins (83), concatamerization and circulariza-
tion (78, 84–86), and transgene expression (87). Notably, the
Mre11/Rad50/Nbs1 (MRN) complex, important for double-
strand break repair, recombination, and telomere maintenance,
has been shown to bind to AAV ITRs, negatively affecting rAAV
transduction, wild-type AAV (wtAAV) replication, and double-
stranded rAAV DNA accumulation (80, 81). It is currently
thought that cellular DNA damage, induced by radiation, small
molecules, or other means, may serve as a “decoy,” recruiting the
MRN complex to the sites of damage and away from single-
stranded AAV DNA, thus allowing for double-strand conversion.
Interestingly, Choi et al. observed that ATM, Mre11, and NBS1 are
required for scAAV DNA circularization in vitro and ATM and
DNA-PK(CS) are required for scAAV DNA circularization in vivo
(84). Taken together, these results suggest that DNA damage re-
sponse proteins may have a dual function in rAAV DNA process-
ing and the positive or negative effects may depend on the state of
the DNA within the cell.
Proteasome inhibition is thought to be beneficial to rAAV
transduction through a mechanism that differs from a DNA dam-
age response. It is believed that inhibition of the proteasome facil-
itates bulk flow of particles away from degradation pathways,
thereby redirecting them to routes that favor transduction (i.e.,
nuclear translocation) (54, 88, 89). Bortezomib, the only currently
FDA-approved proteasome inhibitor, has been used in conjunc-
tion with rAAV to enhance transduction in hemophilia A and
hemophilia B models (43). Its effects seem to be thus far limited to
these applications, as a recent study using rAAV9 to deliver
SERCA2a to preserve cardiac function in a rat model demon-
strated no additional benefit when bortezomib was coadminis-
tered (76). Indeed, our results suggest that the effects of protea-
some inhibition by bortezomib are cell type dependent, as
bortezomib-mediated enhancement was not observed in U87 and
NHF cell lines, and not as robust in HepG2 cells as in HeLa cells.
Interestingly, two compounds that have been previously impli-
cated in proteasome inhibition were identified, physalin B and
siomycin, which outperformed bortezomib in U87, HepG2, and
NHF cell lines. These compounds either may inhibit proteasome
function through a mechanism that is different from that of bort-
ezomib or may perform additional functions in cells that are ben-
eficial to rAAV2 transduction.
The level of involvement of DNA damage response proteins
and proteasome inhibition seems to differ between ssAAV2,
scAAV2, and fAAV2. While the ssAAV2 and fAAV2 used in this
study share identical promoters and luciferase genes, the scAAV2
cassette differed in promoter (CMV versus CBA) as well as trans-
gene (Gaussia versus firefly luciferase). Therefore, a direct com-
parison can be made between ssAAV2 vectors and fAAV2 vectors,
but considerations must be made when evaluating the perfor-
mance of the scAAV2 vector. Initial conclusions seem to indicate
that, for all of the compounds identified in our screen, transduc-
tion enhancement seemed to be less pronounced for scAAV2. This
finding is in agreement with the current theory of how DNA dam-
age proteins may be inhibitory for ssAAV DNA, since scAAV DNA
does not require second-strand synthesis and would therefore be
unaffected by any proteins limiting this type of processing. Since it
has been shown that Mre11 and ATM are required for scAAV
genome circularization, it will be interesting to evaluate the long-
term effects of these compounds on scAAV gene expression in the
future. Interestingly, some enhancement of scAAV2 transduction
was observed with the cotreatment with the epipodophyllotoxins
and anthracyclines, suggesting that these compounds might en-
hance transduction by mechanisms in addition to facilitating sec-
ond-strand synthesis.
Perhaps the most striking observation was the dramatic in-
crease in transduction seen for fAAV2 treated with the com-
pounds identified in this screen. Notably, each compound
boosted fAAV2 transduction to levels greater than in ssAAV2
treated with vehicle alone. Previous studies have shown that
fAAV2 transduction relies on the annealing of sections of vector
DNA that comprise the entire oversized transgene cassette (16).
We previously noted that this process is dependent upon Rad51C,
a single-stranded DNA binding protein involved in supporting
homologous recombination during DNA double-strand break re-
pair (16). Therefore, it is possible that in the case of fAAV2, cellu-
lar DNA damage serves two purposes: (i) derepression of the sin-
gle-stranded cassette by inhibitory proteins such as the MRN
complex and (ii) recruitment of homologous recombination pro-
teins such as Rad51C to facilitate the annealing of fragment vector
DNA. Interestingly, treatment with bortezomib also resulted in
high levels of fAAV2 enhancement. Treatment with proteasome
inhibitors has been shown to increase the sheer volume of vector
particles that reach the nucleus. It is possible that the deficit ob-
served in unassisted fAAV2 transduction is simply a number
FIG 5 Analysis of transduction enhancement by fAAV8 with teniposide in
vivo. (A) Live bioluminescent imaging of mice that were cotreated with
fAAV8_Luc and vehicle (top) or teniposide (bottom), imaged 48 h and 8 days
postransduction. (B) Quantification of bioluminescent imaging. (C) Fold dif-
ference in luciferase expression over vehicles.
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game; i.e., as more particles, and therefore presumably more un-
coated genomes, transit to the nucleus, there is an increased
chance for fragment strand reannealing. Alternatively, inhibition
of the proteasome may also inhibit the degradation of proteins
that might be essential for fAAV2 reannealing. Indeed, work by
Bennett and Knight has shown that proteasome-mediated degra-
dation of Rad51 occurs during DNA repair and this process is
regulated in part by Rad51C (90). Additionally, the proteasome
has been shown to be associated with double-strand breaks and
has been suggested to play a role in degrading proteins upon com-
pletion of DNA repair in yeast (91). Regardless of the mechanism,
our results suggest that the deficit in fAAV2 transduction can be
restored to ssAAV2 levels through pharmacological intervention,
thus paving the way for future studies in pharmaco-gene therapy
for large gene applications.
While the compounds that induced DNA damage seemed to
enhance rAAV transduction to the greatest extent, caution is nec-
essary before potentially moving forward with any of these drugs.
Beyond concerns of direct unwanted side effects of the various
drugs (for example, etoposide has30 undesired consequences),
indirect altered vector maintenance should also be thoroughly
analyzed. Though the primary mechanism of DNA persistence is
through concatamerization and circularization, random integra-
tion has been demonstrated for rAAV (92–97). Indeed, a previous
study has shown that integration of rAAV DNA in vitro increased
upon treatment with etoposide (38, 98). While the epipodophyl-
lotoxins have been shown to produce breaks in DNA “hot spots”
(99–101), a thorough assessment of in vivo integration events
would need to be carried out in order to gauge the risks of this kind
of pharmaco-gene therapy. Finally, the effects of these agents on
episomal expression should also be evaluated. It is tempting to
envision a scenario in which inducing DNA damage through one
of these agents could reactivate persistent-but-silenced rAAV epi-
somes, thus eliminating the need for additional administration of
vector if transgene expression falls below therapeutic levels.
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